Recent Advances in Cystic Fibrosis: Pathophysiology, Molecular Mechanisms and Novel Therapies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 20 May 2024 | Viewed by 358
Special Issue Editor
Interests: cystic fibrosis and CFTR-related diseases; COPD; asthma; interstitial lung diseases; cellular and molecular mechanisms of inflammatory/immune responses; mechanisms of lung injury and repair
Special Issue Information
Dear Colleagues,
Cystic fibrosis (CF) is an autosomal recessive disease that affects mostly the lungs and is caused by mutations in the gene encoding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR absence/dysfunction results in defective ion transport and airway surface liquid dehydration that severely compromise the airway microenvironment, increasing infection susceptibility.
Over the last decade there have been tremendous advances in understanding key elements of the disease and in developing novel therapies leading to improved patient survival.
However, despite these impressive improvements, many questions remain to be addressed such as the mechanisms underlying the persistence of pathogens in CF airways as well as disease progression. Furthermore, the mechanisms of action and the long-term impact of modulator therapy are not fully defined and a proportion of CF patients do not yet have a therapeutic option available.
This Special Issue will focus on the more recent advances in cellular and molecular mechanisms underlying the pathophysiology of CF as well as on novel therapeutic approaches.
We invite investigators to contribute original research articles as well as review articles focusing on mechanisms of airway infection and inflammatory/immune responses in CF as well as on the latest advances in novel therapies at a basic, translational, and clinical level.
Prof. Dr. Virginia De Rose
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cystic fibrosis
- pathophysiology
- molecular pathways and mechanisms
- novel therapies
- CFTR modulators
